Oral GLP‑1s hit mainstream

A hormone drug that was mostly known as a weekly shot is now arriving as a daily pill, with the Food and Drug Administration adding oral semaglutide tablets to Wegovy’s label for chronic weight management in 2026. (accessdata.fda.gov) Semaglutide is a glucagon-like peptide-1 receptor agonist, a medicine that mimics a gut hormone to reduce appetite and slow stomach emptying. The Food and Drug Administration says semaglutide products have been used in diabetes and obesity care, and the updated Wegovy label now lists both injection and oral tablet forms. (fda.gov) (accessdata.fda.gov) The Phase 3 OASIS 4 trial tested oral semaglutide 25 milligrams once a day in 307 adults without diabetes at 22 sites in four countries. At week 64, the oral-semaglutide group had an estimated mean weight change of minus 13.6%, versus minus 2.2% with placebo, and gastrointestinal side effects were reported in 74.0% of treated patients versus 42.2% on placebo. (nejm.org) The same trial found more patients on the pill reached weight-loss thresholds of 5%, 10%, 15%, and 20%, and physical-function scores improved on the Impact of Weight on Quality of Life scale. The study enrolled adults with a body-mass index of at least 30, or at least 27 with one obesity-related complication. (nejm.org) The shift is not just about approval papers. Amazon said in February 2026 that Amazon Pharmacy would expand same-day prescription delivery to nearly 4,500 U.S. cities and towns by the end of the year, adding nearly 2,000 communities. (aboutamazon.com) Eli Lilly’s oral obesity drug, Foundayo, won Food and Drug Administration approval on April 1, 2026, for adults with obesity or overweight with weight-related medical problems. Lilly said the once-daily pill can be taken without food or water restrictions and would ship through LillyDirect starting April 6 before broader retail pharmacy distribution. (prnewswire.com) In Lilly’s ATTAIN-1 trial, patients on the highest Foundayo dose who stayed on treatment lost an average of 27.3 pounds, or 12.4%, compared with 2.2 pounds, or 0.9%, on placebo. Lilly said commercial patients could pay as little as $25 a month, while self-pay pricing would start at $149 a month through LillyDirect. (prnewswire.com) Generic competition is also inching closer. Apotex said on April 10, 2026, that it received the first U.S. Food and Drug Administration tentative approval for a generic semaglutide injection, developed with Orbicular Pharmaceutical Technologies, though the company said final approval would come only when it becomes eligible. (apotex.com) The safety warnings remain the same category of concern that patients and doctors already know from semaglutide products. Wegovy’s prescribing information carries a boxed warning about thyroid C-cell tumors seen in rodents and says the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (accessdata.fda.gov) The result is a market that is starting to look less like a single injectable brand and more like a broader pharmacy category: tablets and shots, brand drugs and would-be generics, mail-order shipping and same-day delivery. The next fight is likely to be over who can get these medicines quickly, consistently, and at a price patients can keep paying. (accessdata.fda.gov) (aboutamazon.com) (apotex.com)